Literature DB >> 10771985

Lower airway disease caused by respiratory syncytial virus.

R Aggarwal1.   

Abstract

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract disease in infants and young children. Most infections due to RSV are mild and do not require hospitalization. RSV causes both upper respiratory tract infections as well as lower respiratory tract infections. Infants with underlying disease states like bronchopulmonary dyslasia, congenital heart disease and prematurity appear more prone to develop severe infection and have a higher incidence of hospitalization. The exact pathogenesis of RSV is not well understood. The mortality associated with primary RSV infection in healthy children is estimated to be between .005% to .02%. In hospitalized children the mortality rate is estimated to be from 1% to 3%. Several treatment modalities in the form of bronchodilators, corticosteroids, ribavirin, intravenous immune gammaglobulin and antibiotics are available. Studies have failed to show the true beneficial effect of any of the above treatment modalities. Supportive care is only needed. The best treatment is the supportive care in the form of oxygen and fluids and close monitoring of the vital signs including oxygen saturation.

Entities:  

Mesh:

Year:  1998        PMID: 10771985     DOI: 10.1007/BF02761127

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  29 in total

1.  American Academy of Pediatrics Committee on Infectious Diseases: Use of ribavirin in the treatment of respiratory syncytial virus infection.

Authors: 
Journal:  Pediatrics       Date:  1993-09       Impact factor: 7.124

2.  Water, electrolyte, and endocrine homeostasis in infants with bronchiolitis.

Authors:  D Gozal; A A Colin; M Jaffe; Z Hochberg
Journal:  Pediatr Res       Date:  1990-02       Impact factor: 3.756

3.  Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; V G Hemming
Journal:  Pediatrics       Date:  1995-04       Impact factor: 7.124

4.  Dexamethasone and salbutamol in the treatment of acute wheezing in infants.

Authors:  A Tal; C Bavilski; D Yohai; J E Bearman; R Gorodischer; S W Moses
Journal:  Pediatrics       Date:  1983-01       Impact factor: 7.124

5.  Pediatric critical care physicians' attitudes about guidelines for the use of ribavirin in critically ill children with respiratory syncytial virus pneumonia.

Authors:  A R Zucker; W L Meadow
Journal:  Crit Care Med       Date:  1995-04       Impact factor: 7.598

6.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; M J Levin; C B Hall; C E Long; W J Rodriguez; J Arrobio; H C Meissner; D R Fulton; R C Welliver
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

7.  Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial.

Authors:  K L Meert; A P Sarnaik; M J Gelmini; M W Lieh-Lai
Journal:  Crit Care Med       Date:  1994-04       Impact factor: 7.598

8.  Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis.

Authors:  K M McConnochie; K J Roghmann
Journal:  Am J Dis Child       Date:  1986-08

9.  Respiratory syncytial virus infection in children with bronchopulmonary dysplasia.

Authors:  J R Groothuis; K M Gutierrez; B A Lauer
Journal:  Pediatrics       Date:  1988-08       Impact factor: 7.124

Review 10.  Respiratory syncytial virus.

Authors:  O Ruuskanen; P L Ogra
Journal:  Curr Probl Pediatr       Date:  1993-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.